68211-13-2

Basic information

• Product Name: 4,6-Dichlorocinnoline
• Synonyms: 4,6-Dichlorocinnoline
• CAS NO: 68211-13-2
• Molecular Formula: C₈H₄Cl₂N₂
• Molecular Weight: 199.03676
• Mol File: 68211-13-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.486
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4,6-Dichlorocinnoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichlorocinnoline(68211-13-2)
• EPA Substance Registry System: 4,6-Dichlorocinnoline(68211-13-2)

Safety Data

• Hazardous Substances Data: 68211-13-2(Hazardous Substances Data)

Usage

General Description

4,6-Dichlorocinnoline is a chemical compound with the molecular formula C8H4Cl2N2. It is a derivative of cinnoline, a heterocyclic aromatic compound. 4,6-Dichlorocinnoline is a white to light yellow crystalline powder that is sparingly soluble in water and organic solvents. It is primarily used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and dyes. The compound is also used as a building block in the production of various specialty chemicals and can be found in research laboratories as a reagent. Its unique structure and reactivity make it a valuable tool in organic synthesis and drug discovery efforts. As with any chemical, proper handling and storage procedures should be followed to ensure safety and prevent environmental contamination.

Upstream product

• 18514-88-0 6-chloro-4(1H)-cinnoline 
• 876-88-0 6-bromo-1H-cinnolin-4-one 
• 10025-87-3 trichlorophosphate 
• 29124-64-9 N-(2-acetyl-4-bromophenyl)acetamide 
• 29124-56-9 1-(2-amino-5-bromophenyl)ethanone 
• 551-93-9 2-aminoacetophenone 

Downstream Products

• 17404-91-0 6-chlorocinnoline 
• 18259-65-9 6-chloro-4-phenoxy-cinnoline 
• 18514-88-0 6-chloro-4(1H)-cinnoline 
• 197359-27-6 6-chloro-4-(2-fluoro-5-hydroxy-4-methylanilino)cinnoline hydrochloride 

Relevant articles and documents

Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR

The identification and lead optimization of a series of pyridopyrimidinone derivatives are described as a novel class of efficacious dual PI3K/mTOR inhibitors, resulting in the discovery of 31. Compound 31 exhibited high enzyme activity against PI3K and mTOR, potent suppression of Akt and p70s6k phosphorylation in cell assays, and good pharmacokinetic profile. Furthermore, compound 31 demonstrated in vivo efficacy in a PC-3M tumor xenograft model.

Cinnoline derivatives and use as medicine

The invention relates to the use of cinnoline derivatives of formula (I) wherein Z represents —O—, —NH—, —S— or —CH2—; m is a n integer from 1 to 5; R1represents hydrogen, hydroxy, halogeno, nitro, cyano, trifluoromethyl, Cp1-3alkyl, C1-3alkoxy, C1-3alkylthio or NR6R7(wherein R6and R7, which may be the same or different, each represents hydrogen or C1-3alkyl); R2represents hydrogen, hydroxy, auoro, chioro, methoxy, amino or nitro; R3represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; R4represents hydrogen, hydroxy, halogeno, cyano, nitro, amino, trifluoromethyl, C1-3alkyl or a group R5—X1(wherein X1represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR8CO—, —CONR9—, —SO2NR10—, —NR11SO2— or NR12— (wherein R8, R9, R10, R11and R12each independently represents hydrogen, C1-3alkyl or C1-3alkoxy C2-3alkyl) and R5is an optionally substituted alkyl, carbocylic or heterocylic group which may be saturated or unsaturated and may be directly linked to the cinnoline ring or be linked via a carbon chain which may have heteroatom linking groups within it and salts thereof, in the manufacture of a medicament for use in the production of an anti angiogenic and/or vascular permeability reducing effect in a warmn-blooded animal such as a human being, processes for the preparation of such derivatives, pharmnaceutical compositions containing a compound of formula (I) or a pharmnaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.